FDA approves Sunosi (solriamfetol) to treat over-day drowsiness associated with OSA syndrome
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today,the FDA(http://announced the approval of Jazz Pharmaceuticals's(http://to treat daytime excessive drowsiness associated with narcolepsy or obstructive sleep apnea (OSA) syndromeAbout Solriamfetol
Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor (DNRI)It can lead to higher levels of dopamine and norepinephrine, which can directly stimulate the wake-up neurons in the brain, while norepinephrine may shut down the sleep driver by acting on the peripheral pre-optic nucleus (VLPO) of the hypothalamusAs a result, thisnew drug(http://may be a dual mechanism to promote patients to stay awakeother current treatments for drowsinessdrug(http://mostly work by stimulating the release of dopamine, which can lead to a surge in dopamine levels and give patients a sense of euphoria, which is at risk of addictionSolriamfetol does not stimulate the release of dopamine, thereby reducing the risk of addictionSolriamfetol's approval is based on a TONES research project that includes a number of Phase 3 clinicaltrials(http://, including to
nES 2 clinical trials for patients with onset sleeping and to
nES 3 and To
nES 4 clinical trials for patients with OSA, as well as to
nES 5 clinical trials to assess long-term safetySolriamfetol not only significantly improved the patient's wakefulness and drowsiness scores in clinical trials, but also demonstrated good safety and tolerance
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
